Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Conatus' Liver Focus Goes Well Beyond NASH

Executive Summary

Biotech believes its pan-caspase inhibitor can treat portal hypertension and also address liver damage in patients with NASH or who've been cured of hepatitis C.


Related Content

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint
Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples
In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner
Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure
Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts